CeriBell’s (NASDAQ:CBLL) Quiet Period To Expire on November 20th

CeriBell’s (NASDAQ:CBLL) quiet period will end on Wednesday, November 20th. CeriBell had issued 10,606,060 shares in its initial public offering on October 11th. The total size of the offering was $180,303,020 based on an initial share price of $17.00. During CeriBell’s quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. William Blair assumed coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “outperform” rating on the stock. Canaccord Genuity Group started coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $30.00 target price on the stock. TD Cowen began coverage on shares of CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $31.00 price objective for the company. Bank of America assumed coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $32.00 price target on the stock. Finally, JPMorgan Chase & Co. began coverage on CeriBell in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $31.20.

CeriBell Price Performance

CBLL stock opened at $25.57 on Wednesday. CeriBell has a twelve month low of $23.00 and a twelve month high of $29.53.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The company had revenue of $17.20 million during the quarter, compared to analyst estimates of $17.06 million. As a group, sell-side analysts forecast that CeriBell will post -2.11 EPS for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.